Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nothing from a company PR, just a IMO feeling that the Canadian news, which is thought to be Costco or Walmart or both, may carry greater impact next week.
I think that the Shareholder Letter set the expectation hammy. Dr.Staelin's comment, "Thus, in Canada we have recently launched the sale of ActiPatch® through a distributor using the same “Try and Tell” program and this distributor is finding similar success. We expect to have some very large sales coming soon. More info will be announced when the ink dries on the purchase orders."
That comment had me looking for something this week also as we have been teased with imminent Canadian news for several weeks now. I think a strategic decision was made to delay the PR until next week.
I think you thinking of NWAV askj. They are the ones with 5 reverse splits under their belt and 9 name changes. BIEL has never tried to hide their share structure with a reverse split. 12+ years and no reverse splits and no name changes.
FDA approval to market in the US opens a new and lucrative market for BIEL. However it is not necessary for BIEL to become a profitable company. Profitability is already on the way with the Lloyds/Gordons 1137 store deal. Do the math. In a few days BIEL will have the 1137 Lloyds/Gordons plus the existing 585 Boots/Walgreens stores. That is a total of 1722 retail stores in the UK.
If one does a conservative estimate and figures 3 units sold per store per day we arrive at 5,166 ActiPatches per day in the UK. Estimating $6-8 profit per unit we hit between $30k and 40k per day,
$900k - 1.2 mil per month. With these sales figures BIEL pays for all expenses with sales revenue, starts paying off debt, and has no need to sell shares.
If you click on the "K number" on any of the submissions on this list you will see that they all have a decision. The FDA does not make any info available to the public on 510k submissions until a decision is reached. Anyone that tells a different story is misinformed.
BIEL has been in business for over 12 years and NEVER has had a reverse split or name change.
New Wave Holdings NWAV is a OTC company that incorporated about the same time as BIEL. NWAV has had 9 name changes and 5 reverse splits.
BIEL is the Real Deal they are not hiding behind name changes and reverse splits.
Pain Management Service from Lloyds Pharmacy
If you suffer from painful conditions and your current medication or treatments aren't relieving the pain, then LloydsPharmacy can help you.
Our pharmacies offer a free Pain Management Service, which involves a one-to-one consultation with either one of our healthcare team or pharmacist, depending on your needs. By listening to your symptoms we will be able to offer advice that suits you.
There are a number of ways we can help you to better manage your pain and simple adjustments to the way your take your medication or to your lifestyle could be all you need to really improve the way you feel.
Who is this service for?
This service is available for anyone who is experiencing acute pain or living with chronic pain.
What will happen during the Pain Management Service?
You will be able to chat to the pharmacist in the privacy of a consultation room. For acute pain, a member of our healthcare team can chat to you more informally, but would be happy to take you through to our consultation room if you'd like to talk in confidence.
Discuss your pain
If you have a short term or intermittent pain (often described as acute pain), a member of our healthcare team will discuss your symptoms with you and what you have already tried.
For more persistent (chronic) pain, our pharmacist will ask questions about the pain you are suffering from and they will fill in a Pain Control Test with you. It will help them to better understand the problems you may be experiencing and help you to set some goals to overcome these.
Great analogy Jimzin! History of Breathe Right, CNS, is a must read for all BIEL investors and potential investors. Before Breathe Right if you had nasal congestion and problems breathing your only option was to take a nasal decongestant drug and drugs affect the entire body. Side effects of included Drowsiness, dizziness, dry mouth/nose/throat, headache, upset stomach, constipation, and trouble sleeping.
Breathe Right solved breathing problems with no drugs, sound familiar? BIEL's ActiPatch does the same thing with pain.
This link explains the history of CNS, the company that makes Breathe Right. http://www.fundinguniverse.com/company-histories/cns-inc-history/
100% correct JustGarden. Walgreens store count will grow from the current 8200 US stores to 12,800 US stores when the deal closes, and BIEL already does business with Boots Walgreens in the UK.
Wow, Lloyds 1,077 stores was a Monster Deal for BIEL. When US OTC hits one deal with Walgreens could put ActiPatch on the shelves of
over 12,000 stores!
Time to get a new calculator dude!
80,000 of the Trial units in the UK sold at $5. This covered the cost of manufacturing and shipping. 50-60% of these customers went on to purchase the 720 hour product, averaging 2-3 units per year. We know this because part of the Trial Program is receiving feedback from the Trial purchaser.
Boots sells the ActiPatch for 19.99 BPS or $22.12 at the current exchange rate.
stockdarock says we are headed to .0075 !!!!!!!!
A 650% increase from today's close !!!!!!!!!!!!!!!!!!
The 7 Day Trial Program has only been used in the UK, to tremendous success, and has started recently in Canada. Dr Staelin explained the brand awareness and limited marketing funds challenges that BIEL faced:
• Lack of money for marketing and no brand awareness caused slow sales growth through distributors
• Decision was made for BIEL to self market through OTC sources
• Boots was the first retailer to sign up, 310 stores, but they would not be promoting the products
• BIEL targeted Chronic Pain and generated a buzz through social media and user testimonials
• $5 Trial Patch extremely successful , 80k sold, allows e-mail customer feedback
• 50-60% of Trial customers go on to purchase 720 hour ActiPatch at a rate of 2-3 per year
• Boots saw the sales numbers and gave ActiPatch more prominent shelf space, added 275 more stores
• Actipatch is the #1 pain remedy on the Boots website
• Lloyds Pharmacy/Gordons 1,137 store deal happened due to the Boots success
• Other retail chains are now inquiring about stocking the ActiPatch
• BIEL has developed an effective, low cost, easily repeatable method to enter new markets
• Customers have strong brand loyalty, tell friends about their pain relief, and are repeat purchasers
• Same program is unfolding in Canada, will be reporting large sales soon
The 72% argument is not valid as the US consumes 80% of the world's pain medication. One of BIEL's big advantages is pain relief with No Addiction and No Side Effects.
Makes perfect sense. BIEL is rapidly expanding and it takes capital to expand a business. Lloyds and Gordons want products in their 1137 stores in November. BIEL needs to have tens of thousands of ActiPatches manufactured and delivered before they get paid by Lloyds and Gordons. The same situation applies to the Canadian expansion.
The 7 Day Trial ActiPatch has been an enormous success. The Trial Program has added Tens of thousands of new customers and covers its own costs. It will be repeated over and over again in each new market that ActiPatch enters.
As Dr. Staelin explained in his Shareholder Letter, BIEL had a small marketing budget and a major marketing task as there was little brand awareness and few consumers who were familiar with PEMF technology. The 7 day Trial hit the bulls-eye.
The 7 Day Trial Program is a good example as to why Dr. Staelin works as a Marketing Professor at one of the most prestigious universities in the US.
Richard Staelin, Ph. D. – Chairman of the Board of Directors
Dr. Staelin joined the Board of Directors in 2005 and has served as Chairman since 2009. He is a Professor at The Fuqua School of Business, Duke University. Past Executive Director of Marketing at the Science Institute and has held numerous positions at the American Marketing Association (AMA) and The Institute of Management Science (TIMS). He was the editorial board member of Marketing Science, Journal of Marketing Research, the Journal of Marketing, the Journal of Consumer Psychology and the Journal of Consumer Research.He has also consulted for the FDA and the FTC.
It is hard to resist adding shares at these bargain prices when you know what is coming.
No logic to this post
BIEL's major retailers are currently Boots/Walgreens and Lloyds Pharmacy both operating stores and online sales in the UK where the ActiPatch is CE Certified. US FDA has no implications for the UK market. Boots has been making money for 2 years with the ActiPatch. Lloyds saw the popularity ActiPatch had at Boots and said sign us up for 1,077 stores. It was not, sign us up when you receive US FDA.
They are interested in their UK market which the ActiPatch has been certified in for several years.
250 new stores would have been Good News.
500 new stores would have been Great News.
750 new stores would have been Fantastic News.
1000 new stores would have been Awesome News.
1137 new stores selling ActiPatch Products, a Major Game Changing Event!!! BIEL has been taking steps in the right direction over the last two years. The 1,077 store deal with Lloyds, plus the bonus 60 Gordons stores was a Giant Leap that caught the attention of numerous major players in the industry.
BIEL is CE and EC Compliant
The Euorpean Union or EU is not the same as the United States of America. The EU has been evolving for the last 20 years but they have no central government agency for functions like the US FDA.
Currently the EU has 74 private companies that are licensed to examine and approve medical devices. When the licensed company, in BIEL's case it is MDSS GmbH in Hanover Germany (visible on sevens picture), confirms that a device meets the CE requirements, in BIEL's case it falls under CE Class 2a, the device is considered CE Certified.
How about that, those liberal Europeans use private enterprise to do the same function as the FDA. If you have any questions regarding the MDSS GmbH certification of BIEL's products they can be reached at (+49)-511-6262 8630 .
Bioeletronics Market Clearance Page
BioElectronics Worldwide Class IIa OTC Market Clearances
BioElectronics Regulatory Logos
US FDA – The treatment of edema following blepharoplasty.
US FDA (Pending) –
RecoveryRx® Indication-of-use: Postoperative pain and edema.
ActiPatch® OTC indication-of-use: Relief of musculoskeletal pain.
Allay® OTCindication-of-use: Relief of menstrual pain and discomfort.
European Union (CE) – For the reduction of pain and Inflammation (OTC).
Health Canada – Relief of pain associated with musculoskeletal complaints, relief of menstrual pain, and postoperative OTC.
Australia (TGA) – For the reduction of pain and inflammation.
Korea – Reduction of muscle pain.
Many others around the world.
http://www.bielcorp.com/distributors/market-clearances/
Expands Into 1,077 Lloyds Pharmacies/60 Gordons Chemists
This week's PR on retail expansion in the UK was AWESOME!!
A 194% increase in an already sizable UK penetration of 585 Boots/Walgreens stores. No matter what the detractors say this is a MAJOR accomplishment for BIEL which can easily move them into the Black. The Canadian Costco/Walmart announcement will be the Cherry on Top.
Costco Canada has 89 stores. When US OTC hits the relationship is there to enter the 474 US stores.
Walmart Canada has 395 stores. When US OTC hits the relationship is there to enter the 4800 US stores.
The PR for Lloyds stated that sales begin on 11/1. But you knew that.
FREDERICK, Md., Oct. 20, 2015 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer pain management medical devices, today announced that it has received initial orders for its ActiPatch® Musculoskeletal Pain Relief products for 1,077 Lloyd's pharmacies, the second largest chain in the UK, and Gordons Chemist. ActiPatch will be on promotion in Lloyd's stores and online beginning November 1.
Zero Triple Zeros
33 million shares traded today and NONE of them were sold in the Triple Zeros, all .001 - .0011 .
We will have to get Santa an invitation the BIEL Penny Celebration!
Ya just know that dude can rock a party.
Notes: Letter to Shareholders R. Staelin Chairman of the Board
• Lack of money for marketing and no brand awareness caused slow sales growth through distributors
• Decision was made for BIEL to self market through OTC sources
• Boots was the first retailer to sign up, 310 stores, but they would not be promoting the products
• BIEL targeted Chronic Pain and generated a buzz through social media and user testimonials
• $5 Trial Patch extremely successful , 80k sold, allows e-mail customer feedback
• 50-60% of Trial customers go on to purchase 720 hour ActiPatch at a rate of 2-3 per year
• Boots saw the sales numbers and gave ActiPatch more prominent shelf space, added 275 more stores
• Actipatch is the #1 pain remedy on the Boots website
• Lloyds Pharmacy/Gordons 1,137 store deal happened due to the Boots success
• Other retail chains are now inquiring about stocking the ActiPatch
• BIEL has developed an effective, low cost, easily repeatable method to enter new markets
• Customers have strong brand loyalty, tell friends about their pain relief, and are repeat purchasers
• Same program is unfolding in Canada, will be reporting large sales soon
• Survey data shows majority of customers getting lasting pain relief creating loyal customer base
• FDA reclassification will help BIEL’s efforts to receive US OTC
• Good clinical data, continuing quality research, survey data, legal expertise will win FDA OTC
• As sales increase BIEL becomes more attractive to partners and distribution agreements
• Moving out of development stage, changing the way people heal and manage pain
The numbers don't quite match your story
30 million shares purchased @ .0011
39 million shares purchased @ .001
Regular Hours BUYS = 69.7 million shares
Regular Hours SELLS = 17.6 million shares
After Hours T-Trade = 21.8 million shares @ .000986
You neglected to mention some important stats.
No Reverse Splits or Name Changes for BIEL for the 12 years they have been in Business. Scam companies hide their true share structure with multiple reverse splits. Name changes are also used to obscure past business history.
Here is an example, New Wave Holdings, NWAV, about the same age as BIEL as it was incorporated in 2003. NWAV has had 9 name changes and 5 reverse splits.
In 2013 BIEL had products on the shelves of 310 Boots/Walgreen stores in the UK. In March of 2015 Boots added 275 stores to the BIEL program, bringing the total to 585 stores. Boots is not a charity. They are in business to make money. BIEL products were selling and Boots was making money so they expanded into 275 more stores.
Lloyds is in the same business as Boots. They saw that Boots was making money with BIEL so the did not need to do a trial. Lloyds jumped in with both feet initiating BIEL in 1,077 Lloyds stores and 60 Gordons stores.
BIEL currently needs capital to fund their expansion which is only available in the form of share value right now. When the income from the Lloyds deal, and the Canadian Costco/Walmart deals which are soon to be announced, start hitting the books the dilution will no longer be required to fund operations.
You missed the point of my post. THE FDA MAKES NO INFORMATION AVAILABLE TO THE PUBLIC ON ANY 510K THAT THEY HAVE RECEIVED UNTIL THEY HAVE COMPLETED THEIR REVIEW AND MADE A DECISION.
Those that say there is no FDA record of BIEL submitting a 510k are the ones trying to scare you.
"Please find the filed 510k"
Please show me any FDA information on a 510k that does not have a decision.
Go to "510kdecisions.com" , click on "Applications", open the "August 2015" button, click on the 510k number "K152404" the first one on the list. It brings up the same info as the FDA 510k Premarket Notification Database.
This is an application that "Abbott" made on "8/25". It received a "SESE" decision on "9/21". All 52 of the 510ks listed for August have a decision.
The FDA assigns the "K" number to 510k submittals when they come in the door. The first two digits are the year, and then next four numbers are assigned sequentially. You will notice gaps in the numbers on the August Application List. This is because these numbers do not have a decision yet. If you go to September you only see 4 listed, because only 4 have a decision.
Our Opioid Binge Finally gets Presidential Attention
It is too bad that it took thousands of lives lost for the US to admit that Opioids and other addictive pain killers kill their patients along with their pain.
"President Barack Obama tackled the opioid epidemic on Wednesday by telling health care providers across the country that access to medication-assisted treatment must be expanded.
For decades, those treating opioid addiction ignored the scientific consensus that the best approach involved medications approved by the Food and Drug Administration, coupled with counseling. Instead, the treatment industry insisted on a model known as "abstinence," in which any prescription medication aimed at addressing a patient's opioid use disorder was forbidden.
Ahead of a Wednesday speech in West Virginia, which has been hit particularly hard by the opioid crisis, Obama essentially said that will end. He released an order giving federal agencies with health care responsibilities 90 days to identify barriers to MAT and to come up with ways to remove them.
"Only a small minority of Americans who might benefit from this treatment are receiving it," the order notes.
A Huffington Post investigation published in January found that the treatment industry overwhelmingly resists a medication-assisted model based on decades-old beliefs about sobriety that have been passed down by those in recovery, but have never been rigorously tested. HuffPost closely examined the treatment histories of 93 people who died of opioid overdoses in a similarly devastated region of Kentucky and found that the majority had received some form of abstinence treatment before dying. The FDA-approved medications that are barred by advocates of abstinence include methadone and buprenorphine, the latter of which was approved more than a decade ago yet still faces stiff resistance.
In February, the White House Office of National Drug Control Policy announced that drug courts which barred addicts from receiving MAT would no longer receive federal funding.
"As the Huffington Post article pointed out, we have highly effective medications, when combined with other behavioral supports, that are the standard of care for the treatment of opiate addiction. And for a long time and what continues to this day is a lack of -- a tremendous amount of misunderstanding about these drugs and particularly within our criminal justice system," drug czar Michael Botticelli said in a briefing with reporters.
Pamela Hyde, the head of the Substance Abuse and Mental Health Services Administration, said at the same briefing that her agency would work to make sure the treatment industry also followed the evidence. "We've made that clear: If they want our federal dollars, they cannot do that," she said of abstinence programs that bar MAT. "We are trying to make it clear that medication-assisted treatment is an appropriate approach to opioids."
The writer of this document was responding to a post by coachpappy on the Yahoo Board. His alias is lakeshore555. The document you read has been changed.
100% correct fuja21.
The FDA approved the ActiBand, predecessor to the ActiPatch, in August of 2002. It had the same 73 microwatt power output as the current ActiPatch operating at the same 27.12 mhz frequency.
Device Classification Name diathermy, shortwave, for use other than applying therapeutic deep heat
510(k) Number K022404
Device Name ACTIBAND
Applicant
PAW, LLC
5540 hidden waters ln.
frederick, MD 21703
Applicant Contact andrew j whelan
Correspondent
PAW, LLC
5540 hidden waters ln.
frederick, MD 21703
Correspodent Contact andrew j whelan
Regulation Number 890.5290
Classification Product Code ILX
Date Received 07/23/2002
Decision Date 08/08/2002
Decision substantially equivalent (SESE)
Regulation Medical Specialty Physical Medicine
510k Review Panel Neurology
statement statement
Type Traditional
Reviewed by Third Party No
Combination Product No
Exactly how are you calculating cost?
The TENS unit mentioned cost $25 and uses a CR2032 battery which according to the reviews can go dead after an hours use on the High setting. Lets say you run it dialed down and get 2 hours out of a battery. A CR2032 runs $2 a unit so your cost per hour after the $25 initial investment is $1 per hour. For 720 hours of therapy your cost totals $743.
ActiPatch runs $29 and uses a CR2032 battery that last for 720 hours. Total cost for 720 hours of therapy is $29. One could purchase 25 ActiPatches for the cost of 720 hours of therapy with your TENS unit.
How did you arrive at your "lower priced" statement?
Thanks for the research yankee. Ordering for 1077 Lloyds and 60 Gordons all at once says a lot about the confidence Lloyds has in the Actipatch. They saw the sales Boots was getting and in the fine capitalist tradition said "Me Too".
I am confident that the BIEL message is getting noticed at the top
of the health care food chain with this deal.
Thanks TBS, all good points and good advice regarding the unpredictable nature of trying to time an exit and reentry at this late stage of the game.
We are over due for the Canadian Costco/Walmart deals to be announced so I am guessing within the next week.
Your observation regarding Boots wanting to protect market share made a lot of sense and they would want to move quickly.
With the Reclass in the bag there could very well be a Licensee or Partner signing up to get a jump on the competition.
News on BIEL's 3 new products that are in clinical trials.
And then there is the wild card of a big pharma or health care company with deep pockets scooping up the whole operation.
Exciting times for BIEL.
Lloyds = Celesio AG = McKesson
Lloyds is owned by Celesio AG. McKesson owns 75% of Celesio AG's stock.
McKesson is the largest Health Care Services Company in North America. BIEL is now connected to McKesson through Celesio and Lloyds.
Celesio AG -
* Has Operations in 14 Countries
* 2200 Pharmacies
* Supplies 4300 Pharmacies through its Brand Partnership Program
* 38k Employees
* Generated $6 Billion in Revenue in the Last Quarter
McKesson -
* No. 1 in Pharmaceutical Distribution in U.S. and Canada
* 52% of U.S. Hospitals use their Technology and Services
* 2,900 Health Mart® Retail Pharmacy Franchisees
* 76k Employees
* Company founded in 1833
* $176 Billion in Yearly Sales
One Major Deal checked off the list today and lots more to come.
10/10/2015 post by mtoronto48
FDA clearance
Walgreens
B. Braun
Canadian retail
Licensed partners
Lloyd's
Boots
Costco
Plus other U.S. retailers
Price target will be in the range of .05 cents to .15 cents if all come to play.
Buyout will be another issue on it's own.
1500 Lloyds and 1077 Stores will stock ActiPatch. Plus Lloyds online.
Fantastic News seven!! And this is just one of several retail/online deals that BIEL is putting the finishing touches on.
I think that you may be a little conservative in your estimates though. If the Lloyds Pharmacists embrace the ActiPatch and advise customers on the benefits of drug free pain relief I see much higher per store sales. This has always been our major obstacle, getting the BIEL story to consumers with limited resources. Now in addition to the power of Boots/Walgreens we have thousands of Lloyds pharmacists to spread the word.
Per provisions of FDASIA, Food and Drug Administration Safety and Innovation Act, the FDA must complete 95% of the 510k submissions received in 2015 within 90 days.
BIEL's submission date was 8/6/2015.
"FDA has committed to review 91% within 90 days for FY 2013 (compared to 90% in 90 days for FY 2012); 93% within 90 days for FY 2014; and 95% within 90 days for FYs 2015 - 2017."
Let's get it correct dd. The price of the AH trade today was .00079.
Pretty easy as it is right here on ihub, Tools/Data Tools/Trades .